Milestone Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Milestone Pharmaceuticals Inc cash flow-to-debt ratio. Milestone Pharmaceuticals Inc (MIST) has a Cash Flow-to-Debt Ratio of -0.15x as of September 2025, meaning its operating cash flow of $-9.82 Million could theoretically repay 0% of its total liabilities ($67.25 Million) in one year. Check how high is Milestone Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Milestone Pharmaceuticals Inc (2017–2024)
Cash flow-to-debt ratio of Milestone Pharmaceuticals Inc from 2017 to 2024. Historical debt coverage capacity for Milestone Pharmaceuticals Inc across 8 annual periods. Check MIST cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Milestone Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
Milestone Pharmaceuticals Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Milestone Pharmaceuticals Inc. For the full cash flow conversion analysis, see MIST cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.46x | $-28.85 Million | $62.35 Million | ▲ +41.7% |
| 2023 | -0.79x | $-46.42 Million | $58.45 Million | ▲ +87.7% |
| 2022 | -6.45x | $-52.47 Million | $8.13 Million | ▼ -40.7% |
| 2021 | -4.58x | $-33.22 Million | $7.25 Million | ▲ +38.1% |
| 2020 | -7.40x | $-50.73 Million | $6.86 Million | ▼ -23.1% |
| 2019 | -6.01x | $-51.15 Million | $8.51 Million | ▼ -3992.0% |
| 2018 | -0.15x | $-21.05 Million | $143.29 Million | ▼ -10.7% |
| 2017 | -0.13x | $-8.05 Million | $60.71 Million | — |